gastroenteritis%20-%20viral
GASTROENTERITIS - VIRAL
Acute gastroenteritis is a diarrheal disease of rapid onset.
Viruses are one of the common causes of gastroenteritis.
Rotavirus, enteric adenovirus serotypes 40 and 41, astrovirus and calicivirus (eg "Norwalk-like" virus) are the established viral agents causing gastroenteritis.
Rotavirus is the most common pathogen causing diarrhea in patients 3-24 months old.
Patients <3 months old are protected by maternal rotavirus antibodies that are passed transplacentally and possibly by breastfeeding.
Transmission is through fecal-oral route.
Incubation period may vary from 1-10 days depending on the causative agent.

Prevention

  • Prevention of most cases of viral gastroenteritis depends on the use of safe and effective vaccines
  • Currently, 2 vaccines are available to prevent severe diarrhea caused by rotavirus infection
    • Several studies support that early vaccination simulate initial natural infection, thus preventing subsequent severe cases of rotavirus gastroenteritis
Human Rotavirus Vaccine
  • Contains live attenuated human rotavirus strain
  • Prevents gastroenteritis caused by the most common genotypes G1P[8], G2P[4], G3P[8], G4P[8] and G9P[8]
    • Effectiveness has also been demonstrated against the less common genotypes G9P[4] and G9P[6] and the uncommon genotypes G8P[4] (severe gastroenteritis) and G12P[6] (any gastroenteritis) 
  • Based on a clinical study done in Asia, the vaccine showed a 100% protective efficacy against severe gastroenteritis during the 1st year of life with the efficacy sustained up to 3 years of age
  • Can be simultaneously administered with the following vaccines without affecting the immune responses and safety profiles of the administered vaccines:
    • Hepatitis B vaccine (HBV)
    • Inactivated polio vaccine (IPV)
    • Haemophilus influenzae type b vaccine (Hib)
    • Pneumococcal conjugate vaccine (PCV)
    • Meningococcal serogroup C conjugate vaccine 
    • Diphtheria-tetanus-acellular pertussis vaccine (DTPa/DTaP)
    • Diphtheria-tetanus-whole cell pertussis vaccine (DTPw/DTwP)
    • Hexavalent vaccines (DTPa-HBV-IPV/Hib)
  • Concomitant administration with oral polio vaccine (OPV) may slightly reduce the immune response to rotavirus vaccine; however, the clinical protection of rotavirus vaccine against severe gastroenteritis would not be affected
    • It is advised that 2 weeks should lapse between administration of the 2 vaccines
Pentavalent Rotavirus Vaccine
  • Contains live reassortant rotaviruses developed from human and bovine hosts
  • Prevents gastroenteritis caused by serotypes G1P1A[8], G2P1[4], G3P1A[8], G4P1A[8] and G9P1A[8]
    • Efficacy in preventing any grade of gastroenteritis severity reached 72.5-74% based on 2 studies done from the time of completion of 3-dose regimen through the 1st rotavirus season after the vaccination
    • The 2 trials also showed that the vaccine has clinical efficacy of 98-100% in preventing severe cases
    • There is a 95.8 % reduction in hospitalizations for severe gastroenteritis during the 1st 2 years following the final dose
  • May be simultaneously administered with the following vaccines without affecting the immune responses of the administered vaccines: HBV, IPV, OPV, Hib, PCV, DTPa, meningococcal serogroup C conjugate vaccine and hexavalent vaccines
  • Concomitant administration with OPV may reduce the immune response to rotavirus vaccine; however, there is evidence that a high level of efficacy against severe gastroenteritis is maintained 
    • It is advised that 2 weeks should lapse between administration of the 2 vaccines
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 13 Jan 2020
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
Stephen Padilla, 6 days ago
The Lancet Commission on Hypertension Group has recently released a position statement that contains a list of recommendations for the improvement of accuracy standards for devices that measure blood pressure (BP).